uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Closed 03-05 16:00:00 EST

10.65

+1.61

+17.81%

盘后10.65

+0.000.00%

19:58 EST

High11.33	Low8.97	Vol9.73M
Open9.04	D1 Closing9.04	Amplitude26.11%
Mkt Cap663.41M	Tradable Cap432.78M	Total Shares62.29M
T/O99.96M	T/O Rate23.94%	Tradable Shares40.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":10.65,"timestamp":1772744400000,"preClose":9.04,"halted":0,"volume":9727712,"hourTrading":{"tag":"盘后","latestPrice":10.65,"preClose":10.65,"latestTime":"19:58 EST","volume":269317,"amount":2864995.9896,"timestamp":1772758737073,"change":0,"changeRate":0,"amplitude":0.028169},"delay":0,"changeRate":0.1780973451327435,"floatShares":40636300,"shares":62291663,"eps":-3.46024,"marketStatus":"Closed","change":1.61,"latestTime":"03-05 16:00:00 EST","open":9.04,"high":11.33,"low":8.97,"amount":99958252.526016,"amplitude":0.261062,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.46024,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772787600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":9.04,"preHourTrading":{"tag":"盘前","latestPrice":9,"preClose":9.04,"latestTime":"09:26 EST","volume":32155,"amount":288565.111605,"timestamp":1772720760003,"change":-0.04,"changeRate":-0.004425,"amplitude":0.040929},"postHourTrading":{"tag":"盘后","latestPrice":10.65,"preClose":10.65,"latestTime":"19:58 EST","volume":269317,"amount":2864995.9896,"timestamp":1772758737073,"change":0,"changeRate":0,"amplitude":0.028169},"volumeRatio":0.927605,"optionData":{"bulkOrders":[{"symbol":"QURE","call":true,"expireDate":1776398400000,"strike":"15.0","timestamp":1772740055116,"price":0.57,"volume":13000,"amount":741000,"type":"+"},{"symbol":"QURE","call":true,"expireDate":1776398400000,"strike":"25.0","timestamp":1772740055116,"price":0.17,"volume":13000,"amount":221000,"type":"-"}]},"impliedVol":1.1871,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/QURE/tweets","defaultTab":"tweets","newsList":[{"id":"2617503557","title":"Rosen Law Firm Highlights April 13 Lead Plaintiff Deadline in uniQure Securities Class Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2617503557","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617503557?lang=en_us&edition=fundamental","pubTime":"2026-03-06 09:09","pubTimestamp":1772759360,"startTime":"0","endTime":"0","summary":"A securities class action has been filed against uniQure NV on behalf of investors who bought its ordinary shares between Sept. 24, 2025 and Oct. 31, 2025. The suit alleges the company misled investors about FDA approval of aspects of its Huntington’s disease pivotal study design and the likelihood of delays to its biologics license application timeline, and it sets an April 13, 2026 deadline for motions to seek lead plaintiff status.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDLdl9Tt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","QURE"],"gpt_icon":0},{"id":"2617573380","title":"Market Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official","url":"https://stock-news.laohu8.com/highlight/detail?id=2617573380","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617573380?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:52","pubTimestamp":1772740345,"startTime":"0","endTime":"0","summary":"UniQure's  experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.The company didn't immediately respond to a request for comment from MT Newswires.Shares of the company were up 13% in Thursday trading.Price: 10.27, Change: +1.23, Percent Change: +13.61","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QURE","LU0889565916.HKD","LU0109394709.USD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2617657882","title":"uniQure therapy called failed product by FDA official, Bloomberg says","url":"https://stock-news.laohu8.com/highlight/detail?id=2617657882","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617657882?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:00","pubTimestamp":1772737236,"startTime":"0","endTime":"0","summary":"In a call with reporters, a senior FDA official said uniQure’s (QURE) gene therapy for Huntington’s disease is a failed product, Gerry Smith and Ro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-therapy-called-failed-product-by-fda-official-bloomberg-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-therapy-called-failed-product-by-fda-official-bloomberg-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0320765992.SGD","QURE","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2617522450","title":"US-Listed Shares of Uniqure Nv Rise Nearly 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617522450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617522450?lang=en_us&edition=fundamental","pubTime":"2026-03-06 01:23","pubTimestamp":1772731387,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL4N3ZT1QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","QURE","BK4139","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2617522930","title":"FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2617522930","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617522930?lang=en_us&edition=fundamental","pubTime":"2026-03-06 01:11","pubTimestamp":1772730660,"startTime":"0","endTime":"0","summary":"FDA official says uniQure's Huntington's gene therapy trial lacked proof of slowing disease, calls for randomized placebo-controlled study.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/05/gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/05/gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/03/51074641/fda-defends-call-for-placebo-study-in-uniqure-huntingtons-gene-therapy-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51074641/fda-defends-call-for-placebo-study-in-uniqure-huntingtons-gene-therapy-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0109394709.USD","QURE","LU0320765992.SGD","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"2617247795","title":"uniQure call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2617247795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617247795?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:45","pubTimestamp":1772729115,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in uniQure (QURE) with 10,055 calls trading, 2x expected, and implied vol increasing almost 3 points to 88.21%. Mar-26...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD","QURE"],"gpt_icon":0},{"id":"2617526102","title":"Concerns spurred by FDA push for ‘sham’ brain surgery trial, Bloomberg says","url":"https://stock-news.laohu8.com/highlight/detail?id=2617526102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617526102?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:56","pubTimestamp":1772722611,"startTime":"0","endTime":"0","summary":"UniQure’s (QURE) gene therapy for Huntington’s disease has shown promising early results, but the FDA is requiring a new trial with a sham-surgery ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/concerns-spurred-by-fda-push-for-sham-brain-surgery-trial-bloomberg-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/concerns-spurred-by-fda-push-for-sham-brain-surgery-trial-bloomberg-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0320765992.SGD","LU0889565916.HKD","QURE","LU0109394709.USD"],"gpt_icon":0},{"id":"2616555977","title":"What's Going On With uniQure Stock Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2616555977","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616555977?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:58","pubTimestamp":1772636280,"startTime":"0","endTime":"0","summary":"QURE hits bearish territory after FDA trial news. With shares near 52-week lows, see the key support and resistance levels to watch.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/04/FDA_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/04/FDA_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4217","QURE","LU0109394709.USD","LU0889565916.HKD","SMA","LU0320765992.SGD"],"gpt_icon":0},{"id":"2616807559","title":"Berger Montague alerts uniQure investors to class action lead plaintiff deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616807559","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616807559?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:37","pubTimestamp":1772635038,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against uniQure NV on behalf of investors who bought or acquired its securities between September 24, 2025 and October 31, 2025. The suit alleges the company misled investors about the design and progress of its AMT-130 pivotal study for Huntington’s disease and the likelihood of accelerated approval, before later disclosing that the FDA did not accept Phase I/II data as sufficient for a BLA submission. Investors seeking appointment as lead plaintiff must file by April 13, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL2gv0vx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","QURE","BK4139","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2616054183","title":"Rosen Law Firm Urges uniQure Investors to Meet April 13 Lead Plaintiff Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616054183","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616054183?lang=en_us&edition=fundamental","pubTime":"2026-03-04 08:36","pubTimestamp":1772584577,"startTime":"0","endTime":"0","summary":"A securities class action has been filed involving uniQure NV on behalf of investors who bought ordinary shares between September 24, 2025 and October 31, 2025. The suit alleges the company misrepresented or failed to disclose issues around FDA approval of its pivotal study design for a Huntington’s disease program and the likelihood of delays to its biologics license application timeline, which allegedly harmed investors when the information emerged. An April 13, 2026 deadline has been set for motions to seek appointment as lead plaintiff.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDLbX42TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","BK4139","LU0320765992.SGD","QURE"],"gpt_icon":0},{"id":"2616532671","title":"These Analysts Cut Their Forecasts On uniQure Following Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2616532671","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616532671?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:34","pubTimestamp":1772548445,"startTime":"0","endTime":"0","summary":"uniQure (NASDAQ:QURE) reported positive Q4 results, but FDA advised against using data for market application of AMT-130. Stock down 13.3%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51000156/these-analysts-cut-their-forecasts-on-uniqure-following-q4-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0109394709.USD","LU0889565916.HKD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2616332814","title":"Chardan Cuts Price Target on uniQure to $16 From $53, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332814","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332814?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:16","pubTimestamp":1772543760,"startTime":"0","endTime":"0","summary":"uniQure (QURE) has an average rating of overweight and mean price target of $31.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","QURE"],"gpt_icon":0},{"id":"2616282473","title":"uniQure Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2616282473","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616282473?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:10","pubTimestamp":1772543400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 08:10 ET (13:10 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2616340023","title":"uniQure price target lowered to $16 from $53 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340023?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:55","pubTimestamp":1772542535,"startTime":"0","endTime":"0","summary":"Chardan lowered the firm’s price target on uniQure (QURE) to $16 from $53 and keeps a Buy rating on the shares after the company held a Type A meet...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-lowered-to-16-from-53-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-lowered-to-16-from-53-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE","LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2616344967","title":"Uniqure Nv : Mizuho Cuts to Neutral From Outperform; Cuts Target Price to $12 From $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616344967?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:51","pubTimestamp":1772538675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0320765992.SGD","QURE","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2616341775","title":"Uniqure Nv : Wells Fargo Cuts to Equal Weight From Overweight; Cuts Target Price to $15 From $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2616341775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616341775?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:38","pubTimestamp":1772537919,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","QURE","LU0109394709.USD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2616345837","title":"Barclays Reaffirms Their Hold Rating on uniQure (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616345837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616345837?lang=en_us&edition=fundamental","pubTime":"2026-03-03 17:45","pubTimestamp":1772531140,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle maintained a Hold rating on uniQure today and set a price target of $31.00. According to TipRanks, Merle is a 3-star ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-hold-rating-on-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-hold-rating-on-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE"],"gpt_icon":0},{"id":"2616331344","title":"uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331344","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331344?lang=en_us&edition=fundamental","pubTime":"2026-03-03 14:01","pubTimestamp":1772517684,"startTime":"0","endTime":"0","summary":"uniQure N.V. (QURE) has disclosed a new risk, in the Economy & Political Environment category. uniQure N.V. is expected to fall under the Dutch lar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/uniqure-faces-2026-shift-to-dutch-large-company-regime-curbing-direct-shareholder-control-over-board-appointments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/uniqure-faces-2026-shift-to-dutch-large-company-regime-curbing-direct-shareholder-control-over-board-appointments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE","LU0889565916.HKD","BK4139","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2616939047","title":"uniQure (QURE) was downgraded to a Hold Rating at Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2616939047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616939047?lang=en_us&edition=fundamental","pubTime":"2026-03-03 13:06","pubTimestamp":1772514398,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear downgraded uniQure to a Hold yesterday and set a price target of $12.00. The company’s shares closed yesterday at ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/uniqure-qure-was-downgraded-to-a-hold-rating-at-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/uniqure-qure-was-downgraded-to-a-hold-rating-at-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","QURE"],"gpt_icon":0},{"id":"2616339926","title":"UniQure (QURE) Posts Q4 Loss Of US$37.1m Reinforcing Profitability Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339926","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339926?lang=en_us&edition=fundamental","pubTime":"2026-03-03 10:22","pubTimestamp":1772504562,"startTime":"0","endTime":"0","summary":"uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over recent quarters, the company has seen revenue move between US$1.6 million and US$5.6 million while basic EPS ranged from a loss of US$0.59 to a loss of US$1.38. This gives investors a clear picture of a business that is still in heavy investment mode rather than focused on near term...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QURE","LU0109394709.USD","LU0889565916.HKD","BK4139","LU0320765992.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":-0.6365},{"period":"1month","weight":-0.634},{"period":"3month","weight":-0.6025},{"period":"6month","weight":-0.4964},{"period":"1year","weight":-0.2021},{"period":"ytd","weight":-0.6222}],"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0148},{"period":"3month","weight":0.0011},{"period":"6month","weight":0.0585},{"period":"1year","weight":0.1877},{"period":"ytd","weight":0.0047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.5,"avgChangeRate":0.032875},{"month":3,"riseRate":0.230769,"avgChangeRate":-0.082393},{"month":4,"riseRate":0.416667,"avgChangeRate":0.018299},{"month":5,"riseRate":0.666667,"avgChangeRate":0.042965},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}